description CRISPR-Cas9 Gene Editing Therapy Overview
CRISPR-Cas9 gene editing is a technology that precisely modifies DNA sequences. It holds significant promise in treating genetic diseases by correcting faulty genes. Currently, it’s primarily utilized in experimental therapies like those targeting sickle cell disease, where cells are modified outside the body before being reintroduced. Researchers and clinicians working in hematology and personalized medicine are exploring its potential for various conditions.
help CRISPR-Cas9 Gene Editing Therapy FAQ
Is CRISPR-Cas9 therapy still experimental, or has it reached real patients?
CRISPR-Cas9 moved from purely experimental work into approved medicine with Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics. The FDA approved Casgevy for sickle cell disease in December 2023 for eligible patients age 12 and older.
How does CRISPR-Cas9 therapy work for sickle cell disease?
For Casgevy, doctors collect a patient's own blood stem cells, edit them outside the body, and reinfuse them after chemotherapy conditioning. The edit targets regulation of fetal hemoglobin, which can reduce the sickling caused by the HBB mutation.
Why is CRISPR therapy not just a simple injection?
Current CRISPR sickle cell treatment is an ex vivo stem-cell procedure, closer to a bone marrow transplant workflow than a normal outpatient shot. It involves cell collection, lab editing, chemotherapy, hospitalization, and long-term follow-up.
What are the biggest risks people ask about with CRISPR-Cas9 therapy?
The major concerns are chemotherapy-related risks, infertility, infection risk during immune suppression, and possible off-target DNA edits. Regulators require long-term monitoring because gene-editing effects can matter years after treatment.
explore Explore More
Similar to CRISPR-Cas9 Gene Editing Therapy
See all arrow_forward
Reviews & Comments
Write a Review
Be the first to review
Share your thoughts with the community and help others make better decisions.
